Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E118.80 EPS (ttm)0.18 Insider Own50.29% Shs Outstand35.78M Perf Week8.70%
Market Cap1.52B Forward P/E- EPS next Y-0.08 Insider Trans-0.26% Shs Float34.84M Perf Month23.31%
Income14.08M PEG- EPS next Q-0.13 Inst Own49.55% Short Float7.75% Perf Quarter37.42%
Sales270.26M P/S5.64 EPS this Y-188.43% Inst Trans-0.13% Short Ratio6.09 Perf Half Y24.09%
Book/sh6.23 P/B3.49 EPS next Y54.77% ROA2.86% Short Interest2.70M Perf Year72.95%
Cash/sh2.94 P/C7.38 EPS next 5Y- ROE3.37% 52W Range10.29 - 21.98 Perf YTD23.95%
Dividend Est.- P/FCF115.70 EPS past 5Y- ROI3.14% 52W High-1.09% Beta0.28
Dividend TTM- Quick Ratio3.85 Sales past 5Y98.80% Gross Margin65.46% 52W Low111.27% ATR (14)0.88
Dividend Ex-Date- Current Ratio4.34 EPS Y/Y TTM-92.44% Oper. Margin-9.32% RSI (14)68.84 Volatility6.25% 4.16%
Employees297 Debt/Eq0.03 Sales Y/Y TTM22.74% Profit Margin5.21% Recom1.00 Target Price27.40
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q455.68% Payout0.00% Rel Volume1.38 Prev Close21.14
Sales Surprise13.84% EPS Surprise455.69% Sales Q/Q34.76% EarningsFeb 28 BMO Avg Volume443.51K Price21.74
SMA2010.48% SMA5014.38% SMA20029.10% Trades Volume614,142 Change2.84%
Date Action Analyst Rating Change Price Target Change
Jun-29-20Reiterated BofA Securities Buy $25 → $40
Apr-01-20Initiated BofA/Merrill Buy $25
Mar-11-19Initiated Barclays Overweight $26
Dec-12-18Reiterated Wedbush Outperform $31 → $33
Jun-19-18Initiated JMP Securities Mkt Outperform $33
Mar-01-24 09:55AM
Feb-29-24 11:33PM
Feb-28-24 08:50AM
08:40AM Loading…
Feb-21-24 04:01PM
Feb-12-24 09:55AM
Jan-23-24 09:55AM
Jan-09-24 08:46AM
Jan-04-24 07:30AM
04:01PM Loading…
Jan-02-24 04:01PM
Dec-23-23 09:00AM
Dec-15-23 02:30PM
Nov-24-23 02:05PM
Nov-20-23 09:55AM
Nov-09-23 10:01PM
Nov-01-23 08:27AM
Oct-31-23 10:48PM
Oct-24-23 04:01PM
Oct-20-23 12:08PM
Sep-29-23 12:43PM
Aug-27-23 08:40AM
Aug-22-23 08:14AM
09:04PM Loading…
Aug-18-23 09:04PM
Aug-10-23 10:33PM
Aug-07-23 06:14AM
Jul-25-23 10:05PM
Jul-24-23 08:31AM
Jul-18-23 04:01PM
Jul-17-23 08:00AM
Jul-04-23 08:24PM
Jun-06-23 04:01PM
May-03-23 06:14AM
May-02-23 08:45AM
May-01-23 04:01PM
Apr-09-23 09:21AM
Apr-05-23 01:40PM
Mar-31-23 09:35AM
Mar-30-23 02:20PM
Mar-29-23 10:13AM
Mar-27-23 12:04PM
Mar-23-23 02:25PM
Mar-03-23 06:57PM
Feb-28-23 11:25AM
Feb-27-23 04:01PM
Feb-23-23 10:50AM
Jan-25-23 02:52AM
Jan-21-23 04:51PM
Jan-09-23 08:00AM
Jan-03-23 04:01PM
Nov-30-22 04:01PM
Nov-23-22 04:01PM
Nov-10-22 09:40AM
Nov-07-22 09:55AM
Nov-01-22 09:15AM
Oct-31-22 04:01PM
Oct-24-22 09:40AM
Oct-05-22 08:50AM
Sep-21-22 12:00PM
Sep-20-22 10:30AM
Sep-12-22 08:30AM
Aug-22-22 09:55AM
Aug-05-22 09:55AM
Aug-04-22 09:09AM
Aug-03-22 04:01PM
Aug-02-22 04:01PM
Jul-22-22 12:00PM
Jun-22-22 09:14AM
Jun-19-22 09:49AM
May-05-22 06:52AM
May-03-22 09:15AM
May-02-22 04:01PM
Apr-13-22 09:08AM
Feb-22-22 09:15AM
Feb-18-22 04:01PM
Jan-10-22 08:00AM
Jan-03-22 04:01PM
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Megna Michael RCHIEF ACCOUNTING OFFICERMar 01Option Exercise10.939,659105,56027,247Mar 01 06:26 PM
Megna Michael RCHIEF ACCOUNTING OFFICERMar 01Sale21.459,659207,18617,588Mar 01 06:26 PM
Megna Michael RCHIEF ACCOUNTING OFFICERFeb 28Option Exercise8.835,12645,26322,714Mar 01 06:26 PM
Megna Michael RCHIEF ACCOUNTING OFFICERFeb 28Sale21.795,126111,69617,588Mar 01 06:26 PM
Paolini John F.CHIEF MEDICAL OFFICERFeb 27Option Exercise1.8610,15618,89055,048Feb 29 04:26 PM
Paolini John F.CHIEF MEDICAL OFFICERFeb 27Sale21.0310,156213,58144,892Feb 29 04:26 PM
Ragosa MarkCHIEF FINANCIAL OFFICERJan 03Option Exercise8.8312,000105,96027,632Jan 04 04:30 PM
Ragosa MarkCHIEF FINANCIAL OFFICERJan 03Sale20.0012,000240,00015,632Jan 04 04:30 PM
Megna Michael RCHIEF ACCOUNTING OFFICERJan 02Option Exercise13.8816,670231,38033,675Jan 04 04:30 PM
Megna Michael RCHIEF ACCOUNTING OFFICERJan 02Sale19.1716,670319,56417,005Jan 04 04:30 PM
Megna Michael RCHIEF ACCOUNTING OFFICERDec 19Option Exercise13.889,316129,30626,321Dec 21 04:26 PM
Megna Michael RCHIEF ACCOUNTING OFFICERDec 19Sale19.139,316178,21517,005Dec 21 04:26 PM
Paolini John F.CHIEF MEDICAL OFFICERDec 07Option Exercise1.8628,60053,19673,492Dec 11 04:20 PM
Paolini John F.CHIEF MEDICAL OFFICERDec 07Sale17.6528,600504,75844,892Dec 11 04:20 PM
Paolini John F.CHIEF MEDICAL OFFICERSep 05Option Exercise1.8640074445,292Sep 06 07:03 PM
Paolini John F.CHIEF MEDICAL OFFICERSep 05Sale17.534007,01244,892Sep 06 07:03 PM
Paolini John F.CHIEF MEDICAL OFFICERJul 25Option Exercise1.8629,00053,94070,910Jul 27 04:30 PM
Paolini John F.CHIEF MEDICAL OFFICERJul 25Sale19.1429,000555,16041,910Jul 27 04:30 PM